- Conditions
- Liver Fibrosis, Alpha-1 Antitrypsin Deficiency, AAT Deficiency, AATD
- Interventions
- Abdominal ultrasound, History and physical, Intravenous catheter, Blood draw, Liver questionnaire, Liver Biopsy, Midazolam, Fentanyl, Lidocaine, Acetaminophen, Lorazepam, Oxycodone/Acetaminophen, Ondansetron
- Device · Procedure · Other + 1 more
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–60
of 60
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- alpha-1 proteinase inhibitor (human)
- Drug
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Gainesville, Florida • Miami, Florida + 5 more
- Conditions
- Chronic Obstructive Pulmonary Disease, Alpha-1 Antitrypsin Deficiency
- Interventions
- six-minute walk study indoors, six-minute walk study outdoors
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Alpha1-antitrypsin Deficiency
- Interventions
- Aerosolized, Recombinant Alpha 1-Antitrypsin
- Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Gainesville, Florida • Cleveland, Ohio + 1 more
- Conditions
- Alpha1-Antitrypsin Deficiency
- Interventions
- Fazirsiran Injection
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 5
- States / cities
- La Jolla, California • Redwood City, California • Gainesville, Florida + 2 more
- Conditions
- Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
- Interventions
- Alpha-1 MP
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 20 Years to 72 Years
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Miami, Florida • Wilmington, North Carolina + 3 more
- Conditions
- Alpha1-Antitrypsin Deficiency
- Interventions
- Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human)
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Gainesville, Florida • Miami, Florida + 2 more
- Conditions
- Alpha-1 Antitrypsin Deficiency
- Interventions
- VX-864
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 10
- States / cities
- Gainesville, Florida • Orlando, Florida • Iowa City, Iowa + 7 more
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- Not listed
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Diabetes, Type 1 Diabetes
- Interventions
- Alpha 1-Antitrypsin (AAT, Aralast NP)
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 6 Years to 45 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Alpha1-antitrypsin Deficiency
- Interventions
- GLASSIA
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Los Angeles, California • Sacramento, California + 13 more
- Conditions
- Pulmonary Emphysema in Alpha-1 PI Deficiency
- Interventions
- Alpha-1 MP, 0.9% Sodium Chloride for Injection, USP
- Biological · Other
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Gainesville, Florida • Leesburg, Florida + 7 more